Fresh off its $14 billion deal for Medivation--and in the midst of considering whether to split in two--Pfizer snapped up a portfolio of high-powered AstraZeneca antibiotics for up to $1.5 billion.
Allergan’s superbug antibiotic Avycaz raked in $22.1 million in sales during H1. But it will be slow going for the rest of 2016 because of an issue with its API maker delaying production until early next year.
